Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Affymetrix Introduces Axiom® miRNA Target Site Genotyping Arrays



  Affymetrix Introduces Axiom® miRNA Target Site Genotyping Arrays

The only commercially available high-density, genome-wide genotyping solution
                  for microRNAs and their mRNA target sites

Business Wire

SANTA CLARA, Calif. -- November 06, 2012

Affymetrix, Inc. (NASDAQ:AFFX) introduces Axiom^® miRNA Target Site Genotyping
Arrays, the only high-density genotyping tools for genome-wide evaluation of
microRNA (miRNA) target sites. These new arrays will enable comprehensive
studies to elucidate how genomic variation in miRNA regulatory machinery
influences gene expression and disease risk. It interrogates 238,000 SNPs and
indels in genes for all parts of the miRNA cascade including miRNAs, their
mRNA target sites, and silencing machinery.

Last month the Encyclopedia of DNA Elements (ENCODE) Consortium, an
international collaboration of research groups funded by the National Human
Genome Research Institute, reported exciting data upending the view that large
portions of the human genome contain “junk” DNA. This non-coding genetic
content has been shown to play a larger role in complex diseases than
previously thought. “We now realize that a portion of this non-coding DNA is
highly relevant in the regulation of translation and plays a role in health
and disease,” stated Andy Last, PhD, Executive Vice President of Genetic
Analysis and Clinical Applications Business Unit at Affymetrix. “These new
arrays are powerful tools for performing large scale genomic analysis of these
important regulatory miRNA elements potentially involved in complex disease.”

These genotyping arrays will complement Affymetrix’ suite of miRNA expression
analysis products, including GeneChip^® miRNA 3.0 Array, QuantiGene^® 2.0
miRNA Assay, and QuantiGene^® ViewRNA in situ Hybridization (ISH) Cell Assay,
which enable comprehensive and integrated analysis to advance our
understanding of the role of gene regulation in health and disease. Over 80
percent of the content on the new Axiom^® miRNA Target Site Genotyping Arrays
is not found on other widely used genotyping arrays and will enable scientists
to survey their sample cohorts against important new content and supplement
their existing association studies via meta-analysis.

“The studies we are performing using the Axiom^® miRNA Target Site Genotyping
Array are showing promising results,” stated Professor Stephen B. Gruber,
M.D., Ph.D., M.P.H., Director of the USC Norris Comprehensive Cancer Center,
Keck School of Medicine of the University of Southern California. “We believe
this array, focused on detecting variation in miRNA regulatory machinery,
represents a new opportunity to broadly interrogate an important class of
variants relevant to cancer research.”

In addition to the predesigned catalog version, customers can easily choose to
add their own content to Axiom^® miRNA Target Site Genotyping Arrays,
including variants in long non-coding RNAs for disease association studies.

Preliminary studies with the new array will be presented at the 2012 annual
meeting of the American Society of Human Genetics (ASHG) in San Francisco at
10:40 a.m. on November 10, 2012. The talk, entitled “Case-control study of
microRNA target site polymorphisms and colorectal cancer in the Ashkenazi
Jewish population” will be presented by Dr. Michael Shapero, Sr. Director of
Molecular Genetics, Affymetrix.

Axiom^® miRNA Target Site Genotyping Arrays are available now and custom
versions of the array can be delivered in 4-6 weeks.

Products mentioned in this release are for research use only. Not for
diagnostic procedures.

PLEASE NOTE: Affymetrix^®, the Affymetrix logo, Axiom^®, GeneChip^®,
QuantiGene^®, and all other trademarks are the property of Affymetrix, Inc.
All other trademarks are the property of their respective owners.

About Affymetrix

Affymetrix technologies are used by the world's top pharmaceutical,
diagnostic, and biotechnology companies as well as leading academic,
government, and nonprofit research institutes. More than 26,000 peer-reviewed
papers have been published citing the technologies. Affymetrix is
headquartered in Santa Clara, Calif., and has manufacturing facilities in
Santa Clara, San Diego, Cleveland, Ohio, Singapore, and Austria. The company
has about 1,180 employees worldwide and maintains sales and distribution
operations across Europe, Asia, and Latin America. For more information about
Affymetrix, please visit www.affymetrix.com.

Forward-looking statements

All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies," or the like.
Such statements are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the year ended
December 31, 2011, and other SEC reports for subsequent quarterly periods.

Contact:

Affymetrix, Inc.
Media Contact:
Mindy Lee-Olsen, 408-731-5523
Vice President, Marketing Services
mindy_lee-olsen@affymetrix.com
or
Investor Contact:
Doug Farrell, 408-731-5285
Vice President, Investor Relations
doug_farrell@affymetrix.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement